Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Olivier Petricoul"'
Autor:
Thomas Hach, Kasra Shakeri-Nejad, Marc Bigaud, Frank Dahlke, Massimiliano de Micco, Olivier Petricoul, Gordon Graham, Daniela Piani-Meier, Renato Turrini, Volker Brinkmann, Ferdinando Nicoletti
Publikováno v:
Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research.
Maladjusted immune responses to the coronavirus disease 2019 (COVID-19), for example, cytokine release syndrome, may result in immunopathology and acute respiratory distress syndrome. Sphingosine-1-phosphate (S1P), a bioactive lipid mediator, and its
Autor:
Olivier Petricoul, Arman Nazarian, Uwe Schuehly, Ursula Schramm, Olivier J. David, Didier Laurent, Jens Praestgaard, Ronenn Roubenoff, Dimitris A. Papanicolaou, Daniel Rooks
Publikováno v:
Clinical pharmacokinetics.
Bimagrumab is a human monoclonal antibody binding to the activin type II receptor with therapeutic potential in conditions of muscle wasting and obesity. This phase I study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), and safety of var
Autor:
Jens Praestgaard, Ronenn Roubenoff, Olivier Petricoul, Didier Laurent, Daniel Rooks, Michael Bartlett
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle
Background Bimagrumab prevents activity of myostatin and other negative regulators of skeletal muscle mass. This randomized double-blind, placebo-controlled study investigated safety, pharmacokinetics (PK), and pharmacodynamics of bimagrumab in healt
Autor:
Yue Li, Claudia Simonett, Esther Kamphausen, Louise Mooney, Stephen John Oliver, Maciej Cabanski, Thomas Dörner, Andreas Hüser, Olivier Petricoul, Frank Wagner, Marie-Anne Valentin, Hermann Gram, Julie Milojevic, Maximilian G. Posch
Publikováno v:
Annals of the Rheumatic Diseases. 78:641-647
ObjectivesTo evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s syndrome (pSS) in a double-blind, placebo-controlle
Autor:
Jens Praestgaard, Liang Kung Chen, Hidenori Arai, Olivier Petricoul, Budhaditya Goswami, Dimitris Papanicolaou, John Vissing, Yoon Sok Chung, Chris Recknor, Estelle Lach-Trifilieff, Jun Hashimoto, Laura A. Coleman, Nicolas Panchaud, Ram R. Miller, Lee Anne Filosa, Didier Laurent, Robert G. Perry, Sarah Hemsley, Charles M. Fogarty, Ola Bunte, Ronenn Roubenoff, Daniel Rooks, Therese Swan, Elisa Garcia Garayoa
Publikováno v:
Rooks, D, Swan, T, Goswami, B, Filosa, L A, Bunte, O, Panchaud, N, Coleman, L A, Miller, R R, Garcia Garayoa, E, Praestgaard, J, Perry, R G, Recknor, C, Fogarty, C M, Arai, H, Chen, L K, Hashimoto, J, Chung, Y S, Vissing, J, Laurent, D, Petricoul, O, Hemsley, S, Lach-Trifilieff, E, Papanicolaou, D A & Roubenoff, R 2020, ' Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults : A Randomized Clinical Trial ', JAMA Network Open, vol. 3, no. 10, e2020836 . https://doi.org/10.1001/jamanetworkopen.2020.20836
JAMA Netw Open
JAMA Netw Open
Importance: The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown. Objective: To confirm the safety and efficacy of bimagrumab plus the new s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2548e2635b4203a261b60319a8a0f71d
https://curis.ku.dk/ws/files/253352215/Bimagrumab_vs_Optimized_Standard_of_Care_for_Treatment_of_Sarcopenia.pdf
https://curis.ku.dk/ws/files/253352215/Bimagrumab_vs_Optimized_Standard_of_Care_for_Treatment_of_Sarcopenia.pdf
Autor:
Srikanth Neelakantham, Ronenn Roubenoff, Tania Garito, Daniel Rooks, Linda Morrow, Charles D. Meyers, Olivier Petricoul, Lee Anne Filosa, Katherine Gomez, Marcus Hompesch, Marjorie Zakaria, Monte S. Buchsbaum, Therese Swan, Didier Laurent
Publikováno v:
Diabetes, Obesity and Metabolism. 20:94-102
Background Skeletal muscle is a key mediator of insulin resistance. Bimagrumab, an antibody against activin receptor type II (ActRII), prevents binding of negative muscle regulators, like myostatin, and increases lean mass and decreases fat mass in a
Autor:
Didier Laurent, Sam Hariry, Jens Praestgaard, Daniel Rooks, Olivier Petricoul, Robert G. Perry, Ronenn Roubenoff, Estelle Lach-Trifilieff
Publikováno v:
Journal of the American Geriatrics Society. 65:1988-1995
Objectives To assess the effects of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. Design A 24-week, randomized, double-blind, placebo-controlled, parallel-arm, proof-of-concept study. Settin
Autor:
Laura A. Coleman, Didier Laurent, Steven B. Heymsfield, Daniel Rooks, Thomas Wade, Jens Praestgaard, Olivier Petricoul, Bret H. Goodpaster, Therese Swan, Ram R. Miller, Ronenn Roubenoff, Robert G. Perry
Publikováno v:
JAMA Network Open
Antibody blockade of activin type II receptor (ActRII) signaling stimulates skeletal muscle growth. Previous clinical studies suggest that ActRII inhibition with the monoclonal antibody bimagrumab also promotes excess adipose tissue loss and improves
Autor:
Christopher Grunseich, Ram Miller, Therese Swan, David J Glass, Mohamed El Mouelhi, Mara Fornaro, Olivier Petricoul, Igor Vostiar, Ronenn Roubenoff, Matthew N Meriggioli, Angela Kokkinis, Robert D Guber, Maher S Budron, John Vissing, Gianni Soraru, Tahseen Mozaffar, Albert Ludolph, John T Kissel, Kenneth H Fischbeck, Julia Dahlqvist, Nanna Witting, Ilaria Martinelli, Giorgia Querin, Namita A Goyal, Tiyonnoh M Cash, Brian Minton, Angela Rosenbohm, Ulrike Weiland, Patrick Weydt, Sharon Chelnick, Stanley Iyadurai, Wendy King
Publikováno v:
The Lancet. Neurology. 17(12)
Summary Background Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease caused by CAG repeat expansion in the androgen receptor gene. Patients with this disease have low concentrations of insulin-like growth factor-1 (IGF-1), and s
Autor:
Juan Carlos Rondon, Daniel Rooks, Dimitris Papanicolaou, Pascale Pinot, Didier Laurent, Olivier Petricoul, Yifang Li, Tania Garito, Ronenn Roubenoff, Marjorie Zakaria
Publikováno v:
Clinical endocrinology. 88(6)
BACKGROUND Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle growth. Bimagrumab is under ev